U.S. Drug Sales Top $329 Billion In 2013, Up 3.2% – IMS Report
This article was originally published in The Pink Sheet Daily
Executive Summary
IMS Health’s report on U.S. drug spending in 2013 shows a return to growth last year after a decline in 2012, with a lower impact of brands losing patent protection being an important factor, as well as brand price increases.
You may also be interested in...
Speciality Drugs, ‘Pharmerging’ Markets Key Drivers Of Global Rx Growth
IMS forecasts global pharmaceutical spending will reach $1.3 trillion in 2018, 30% higher than in 2013, with specialty drugs a key driver of forecast global growth. Within the major Asian markets, Japan has a generally low growth outlook while China will lead the ‘pharmerging’ countries with solid sales expansion, despite growing budget pressures.
Pharmaceutical Spending Fell Slightly; A First, Says IMS Institute
IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.